156 related articles for article (PubMed ID: 9493588)
1. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of plasma coagulation and platelet activation during experimental long-term perfusion.
Skogby M; Friberg LG; Adrian K; Mellgren K
Scand Cardiovasc J; 2003 Sep; 37(4):222-8. PubMed ID: 12944211
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation.
Sundaram S; Gikakis N; Hack CE; Niewiarowski S; Edmunds LH; Koneti Rao A; Sun L; Cooper SL; Colman RW
Thromb Haemost; 1996 Jan; 75(1):76-82. PubMed ID: 8713783
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
[TBL] [Abstract][Full Text] [Related]
5. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
6. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.
Hiramatsu Y; Homma S; Sato Y; Sato S; Matsuzaki K; Shigeta O; Sakakibara Y
Ann Thorac Surg; 2005 Apr; 79(4):1326-32. PubMed ID: 15797071
[TBL] [Abstract][Full Text] [Related]
9. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
[TBL] [Abstract][Full Text] [Related]
10. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
11. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
13. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
[TBL] [Abstract][Full Text] [Related]
14. The effect of epoprostenol on platelet activation and consumption during experimental extracorporeal perfusion.
Skogby M; Adrian K; Friberg L; Mellgren K
Artif Organs; 1999 Nov; 23(11):984-7. PubMed ID: 10564302
[TBL] [Abstract][Full Text] [Related]
15. Nafamostat mesilate reduces blood cell adhesion to cardiopulmonary bypass circuits: an in-vitro study.
Hiroura M; Usui A; Kawamura M; Hibi M; Iwase J
J Extra Corpor Technol; 1994 Sep; 26(3):121-5. PubMed ID: 10150679
[TBL] [Abstract][Full Text] [Related]
16. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
17. [The inhibitory effect of nafamostat mesilate (FUT-175) on liver metastasis].
Kimura T; Fuchimoto S; Iwagaki H; Orita K
Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):66-70. PubMed ID: 8437554
[TBL] [Abstract][Full Text] [Related]
18. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
19. [The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis].
Heitz J; Semsch B; Emde C; Jansen U; Schäfer JH
Z Gastroenterol; 1990 Apr; 28(4):192-7. PubMed ID: 2119091
[TBL] [Abstract][Full Text] [Related]
20. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
